Literature DB >> 11592118

Distribution of intraventricularly administered antiamyloid-beta peptide (Abeta) antibody in the mouse brain.

N B Chauhan1, G J Siegel, T Lichtor.   

Abstract

There is considerable interest in utilizing the intracerebroventricular (icv) route of administration of antibodies in the brain for various studies and for the therapy of malignancies, but very little is known about the anatomic extent of distribution of the antibody in brain after injection into the third ventricle. To explore the potential for icv administration of antiamyloid-beta peptide (Abeta) in reducing Abeta toxicity in brain in Alzheimer's disease, we first mapped the time course and path of transit of horseradish peroxidase (HRP)-labeled antibody. The results show that, after a single injection into the mouse third venticle, the HRP-labeled antibody is localized within the microvasculature, first that of the corticohippocampal region close to the site of injection at 3 hr. By 24 hr, the antibody is distributed throughout the hippocampus and frontoparietal cortex close to the injection site, as well as in the deep and outer cerebral cortex and cerebellar cortex remote from the injection site. The injected antibody is almost entirely removed by 4 days. Therefore, the antibody had diffused throughout all the brain by 24 hr, showing the feasibility of small quantities of anti-Abeta antibody infused into the third ventricle to reach extracellular epitopes throughout the brain parenchyma rapidly. Published 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592118     DOI: 10.1002/jnr.1215

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  8 in total

Review 1.  Vaccines for Alzheimer's disease: how close are we?

Authors:  Christopher Janus
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches.

Authors:  Niyanta N Kumar; Michelle E Pizzo; Geetika Nehra; Brynna Wilken-Resman; Sam Boroumand; Robert G Thorne
Journal:  Bioconjug Chem       Date:  2018-10-24       Impact factor: 4.774

3.  Wheat germ agglutinin enhanced cerebral uptake of anti-Aβ antibody after intranasal administration in 5XFAD mice.

Authors:  Neelima B Chauhan; Francesca Davis; Chun Xiao
Journal:  Vaccine       Date:  2011-08-12       Impact factor: 3.641

4.  Antisense inhibition at the beta-secretase-site of beta-amyloid precursor protein reduces cerebral amyloid and acetyl cholinesterase activity in Tg2576.

Authors:  Neelima B Chauhan; George J Siegel
Journal:  Neuroscience       Date:  2007-02-14       Impact factor: 3.590

Review 5.  Effects of gonadotrophin-releasing hormone outside the hypothalamic-pituitary-reproductive axis.

Authors:  D C Skinner; A J Albertson; A Navratil; A Smith; M Mignot; H Talbott; N Scanlan-Blake
Journal:  J Neuroendocrinol       Date:  2009-03       Impact factor: 3.627

6.  CD8+ T cells maintain suppression of simian immunodeficiency virus in the central nervous system.

Authors:  Maria Cecilia G Marcondes; Brenda Morsey; Katy Emanuel; Benjamin G Lamberty; Claudia T Flynn; Howard S Fox
Journal:  J Infect Dis       Date:  2014-07-17       Impact factor: 5.226

7.  Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice.

Authors:  Deepak R Thakker; Marcy R Weatherspoon; Jonathan Harrison; Thomas E Keene; Deanna S Lane; William F Kaemmerer; Gregory R Stewart; Lisa L Shafer
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-25       Impact factor: 11.205

8.  Delivery of an anti-transthyretin Nanobody to the brain through intranasal administration reveals transthyretin expression and secretion by motor neurons.

Authors:  João R Gomes; Inês Cabrito; Hugo R Soares; Susete Costelha; Anabela Teixeira; Angela Wittelsberger; Catelijne Stortelers; Peter Vanlandschoot; Maria J Saraiva
Journal:  J Neurochem       Date:  2018-05-09       Impact factor: 5.372

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.